The Montana Cancer Consortium (MCC) NCORP Community Site will coordinate, support and improve the activities of physicians, cancer centers and hospitals across the entire state of Montana, as w/ell as portions of Northern Idaho and Wyoming, to maximize patient access to the highest levels of cancer care, especially accrual to NCI-sponsored clinical trials. In addition, MCC NCORP will design, participate in and influence cancer care delivery research, helping inform and speed validated care innovations into clinical practice. The region has been characterized as 'mega-rural'with severe access to care due to the vastness of the geography, lack of university-based treatment and research facilities, and lack of primary care providers. It is also home to seven American Indian Reservations, where issues of poverty, distance, and cultural taboos surrounding cancer care discussion and treatment create special disparities to prevention, early diagnosis, treatment and survivorship of cancer. MCC is an independent not-for-profit institution that exists to maximize access to clinical treatment trials and research through centralized services and support for member physicians and sites that might not otherwise offer access to these critical opportunities. The MCC NCORP Community Site consists of ten member components and six subcomponents that collectively will serve over one million residents in an area covering over 200,000 square miles. Membership includes 53 Board Certified oncologists, virtually every practitioner in the region and their respective hospitals and clinics, representing all cancer car specialty areas. MCC core staff managed the NCI Community Cancer Oncology Program (CCOP) since 1996 and includes a component site selected as an NCI National Community Cancer Centers Program (NCCCP) since 2007. MCC NCORP is affiliated with five national research bases, and is poised to provide and support expanded access to state-of-the-art cancer treatment, prevention, and control through NCI-sponsored clinical trials while improving the delivery of cancer care through research.

Public Health Relevance

The uniquely rural and medically underserved population of Montana, Northern Idaho and Northern Wyoming offers stimulating challenges for implementing NCI-sponsored clinical trials. The collective experience of the component sites in successful clinical trial enrollment and care delivery research on both rural and American Indian underserved populations will benefit NCORP's diversity and disparity goals.

National Institute of Health (NIH)
National Cancer Institute (NCI)
Clinical Research Cooperative Agreements - Single Project (UG1)
Project #
Application #
Study Section
Special Emphasis Panel (ZCA1-RTRB-E (M1))
Program Officer
Pearson, Deborah
Project Start
Project End
Budget Start
Budget End
Support Year
Fiscal Year
Total Cost
Indirect Cost
Montana Cancer Consortium
United States
Zip Code
West, Howard L; Moon, James; Wozniak, Antoinette J et al. (2018) Paired Phase II Studies of Erlotinib/Bevacizumab for Advanced Bronchioloalveolar Carcinoma or Never Smokers With Advanced Non-Small-cell Lung Cancer: SWOG S0635 and S0636 Trials. Clin Lung Cancer 19:84-92
Henry, N Lynn; Unger, Joseph M; Schott, Anne F et al. (2018) Randomized, Multicenter, Placebo-Controlled Clinical Trial of Duloxetine Versus Placebo for Aromatase Inhibitor-Associated Arthralgias in Early-Stage Breast Cancer: SWOG S1202. J Clin Oncol 36:326-332
Hussain, Maha; Tangen, Catherine M; Thompson Jr, Ian M et al. (2018) Phase III Intergroup Trial of Adjuvant Androgen Deprivation With or Without Mitoxantrone Plus Prednisone in Patients With High-Risk Prostate Cancer After Radical Prostatectomy: SWOG S9921. J Clin Oncol 36:1498-1504
Flaig, Thomas W; Plets, Melissa; Hussain, Maha H A et al. (2017) Abiraterone Acetate for Metastatic Prostate Cancer in Patients With Suboptimal Biochemical Response to Hormone Induction. JAMA Oncol 3:e170231
Yao, James C; Guthrie, Katherine A; Moran, Cesar et al. (2017) Phase III Prospective Randomized Comparison Trial of Depot Octreotide Plus Interferon Alfa-2b Versus Depot Octreotide Plus Bevacizumab in Patients With Advanced Carcinoid Tumors: SWOG S0518. J Clin Oncol 35:1695-1703
Sekeres, Mikkael A; Othus, Megan; List, Alan F et al. (2017) Randomized Phase II Study of Azacitidine Alone or in Combination With Lenalidomide or With Vorinostat in Higher-Risk Myelodysplastic Syndromes and Chronic Myelomonocytic Leukemia: North American Intergroup Study SWOG S1117. J Clin Oncol 35:2745-2753
McWilliams, Robert R; Foster, Nathan R; Mahoney, Michelle R et al. (2017) North Central Cancer Treatment Group N0543 (Alliance): A phase 2 trial of pharmacogenetic-based dosing of irinotecan, oxaliplatin, and capecitabine as first-line therapy for patients with advanced small bowel adenocarcinoma. Cancer 123:3494-3501
Danilov, Alexey V; Li, Hongli; Press, Oliver W et al. (2017) Feasibility of interim positron emission tomography (PET)-adapted therapy in HIV-positive patients with advanced Hodgkin lymphoma (HL): a sub-analysis of SWOG S0816 Phase 2 trial. Leuk Lymphoma 58:461-465
Moinpour, Carol M; Unger, Joseph M; Ganz, Patricia A et al. (2017) Seven-year follow-up for energy/vitality outcomes in early stage Hodgkin's disease patients treated with subtotal lymphoid irradiation versus chemotherapy plus radiation: SWOG S9133 and its QOL companion study, S9208. J Cancer Surviv 11:32-40
Durie, Brian G M; Hoering, Antje; Abidi, Muneer H et al. (2017) Bortezomib with lenalidomide and dexamethasone versus lenalidomide and dexamethasone alone in patients with newly diagnosed myeloma without intent for immediate autologous stem-cell transplant (SWOG S0777): a randomised, open-label, phase 3 trial. Lancet 389:519-527

Showing the most recent 10 out of 19 publications